Clinical Pharmacokinetics

, Volume 48, Issue 12, pp 761–804 | Cite as

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

Part II
Review Article

Abstract

Part I of this article discussed the potential functional importance of genetic mutations and alleles of the human cytochrome P450 2D6 (CYP2D6) gene. The impact of CYP2D6 polymorphisms on the clearance of and response to a series of cardiovascular drugs was addressed. Since CYP2D6 plays a major role in the metabolism of a large number of other drugs, Part II of the article highlights the impact of CYP2D6 polymorphisms on the response to other groups of clinically used drugs.

Although clinical studies have observed a gene-dose effect for some tricyclic antidepressants, it is difficult to establish clear relationships of their pharmacokinetics and pharmacodynamic parameters to genetic variations of CYP2D6; therefore, dosage adjustment based on the CYP2D6 phenotype cannot be recommended at present. There is initial evidence for a gene-dose effect on commonly used selective serotonin reuptake inhibitors (SSRIs), but data on the effect of the CYP2D6 genotype/phenotype on the response to SSRIs and their adverse effects are scanty. Therefore, recommendations for dose adjustment of prescribed SSRIs based on the CYP2D6 genotype/phenotype may be premature.

A number of clinical studies have indicated that there are significant relationships between the CYP2D6 genotype and steady-state concentrations of perphenazine, zuclopenthixol, risperidone and haloperidol. However, findings on the relationships between the CYP2D6 genotype and parkinsonism or tardive dyskinesia treatment with traditional antipsychotics are conflicting, probably because of small sample size, inclusion of antipsychotics with variable CYP2D6 metabolism, and co-medication. CYP2D6 phenotyping and genotyping appear to be useful in predicting steady-state concentrations of some classical antipsychotic drugs, but their usefulness in predicting clinical effects must be explored. Therapeutic drug monitoring has been strongly recommended for many antipsychotics, including haloperidol, chlorpromazine, fluphenazine, perphenazine, risperidone and thioridazine, which are all metabolized by CYP2D6. It is possible to merge therapeutic drug monitoring and pharmacogenetic testing for CYP2D6 into clinical practice.

There is a clear gene-dose effect on the formation of O-demethylated metabolites from multiple opioids, but the clinical significance of this may be minimal, as the analgesic effect is not altered in poor metabolizers (PMs). Genetically caused inactivity of CYP2D6 renders codeine ineffective owing to lack of morphine formation, decreases the efficacy of tramadol owing to reduced formation of the active O-desmethyltramadol and reduces the clearance of methadone. Genetically precipitated drug interactions might render a standard opioid dose toxic.

Because of the important role of CYP2D6 in tamoxifen metabolism and activation, PMs are likely to exhibit therapeutic failure, and ultrarapid metabolizers (UMs) are likely to experience adverse effects and toxicities. There is a clear gene-concentration effect for the formation of endoxifen and 4-OH-tamoxifen. Tamoxifen-treated cancer patients carrying CYP2D6*4, *5, *10, or *41 associated with significantly decreased formation of antiestrogenic metabolites had significantly more recurrences of breast cancer and shorter relapse-free periods. Many studies have identified the genetic CYP2D6 status as an independent predictor of the outcome of tamoxifen treatment in women with breast cancer, but others have not observed this relationship. Thus, more favourable tamoxifen treatment seems to be feasible through a priori genetic assessment of CYP2D6, and proper dose adjustment may be needed when the CYP2D6 genotype is determined in a patient.

Dolasetron, ondansetron and tropisetron, all in part metabolized by CYP2D6, are less effective in UMs than in other patients. Overall, there is a strong gene-concentration relationship only for tropisetron. CYP2D6 genotype screening prior to antiemetic treatment may allow for modification of antiemetic dosing. An alternative is to use a serotonin agent that is metabolized independently of CYP2D6, such as granisetron, which would obviate the need for genotyping and may lead to an improved drug response.

To date, the functional impact of most CYP2D6 alleles has not been systematically assessed for most clinically important drugs that are mainly metabolized by CYP2D6, though some initial evidence has been identified for a very limited number of drugs. The majority of reported in vivo pharmacogenetic data on CYP2D6 are from single-dose and steady-state pharmacokinetic studies of a small number of drugs. Pharmacodynamic data on CYP2D6 polymorphisms are scanty for most drug studies. Given that genotype testing for CYP2D6 is not routinely performed in clinical practice and there is uncertainty regarding genotype-phenotype, gene-concentration and gene-dose relationships, further prospective studies on the clinical impact of CYP2D6-dependent metabolism of drugs are warranted in large cohorts.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

References

  1. 1.
    Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48: 689–723PubMedCrossRefGoogle Scholar
  2. 2.
    Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin Pharmacol Ther 2007; 82: 606–9PubMedCrossRefGoogle Scholar
  3. 3.
    Hollister LE. Tricyclic antidepressants (first of two parts). N Engl J Med 1978; 299: 1106–9PubMedCrossRefGoogle Scholar
  4. 4.
    Mellstrom B, von Bahr C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab Dispos 1981; 9: 565–8PubMedGoogle Scholar
  5. 5.
    Venkatakrishnan K, Von Moltke LL, Obach RS, et al. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J Pharmacol Exp Ther 2000; 293: 343–50PubMedGoogle Scholar
  6. 6.
    Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001; 41: 1043–54PubMedCrossRefGoogle Scholar
  7. 7.
    Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25: 740–4PubMedGoogle Scholar
  8. 8.
    Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004; 36: 723–46PubMedCrossRefGoogle Scholar
  9. 9.
    Breyer-Pfaff U, Pfandl B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350–8PubMedCrossRefGoogle Scholar
  10. 10.
    Dahl ML, Nordin C, Bertilsson L. Enantioselective hydroxylation of nortriptyline in human liver microsomes, intestinal homogenate, and patients treated with nortriptyline. Ther Drug Monit 1991; 13: 189–94PubMedCrossRefGoogle Scholar
  11. 11.
    Nordin C, Bertilsson L. Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995; 28: 26–40PubMedCrossRefGoogle Scholar
  12. 12.
    Mellstrom B, Sawe J, Bertilsson L, et al. Amitriptyline metabolism: association with debrisoquin hydroxylation in nonsmokers. Clin Pharmacol Ther 1986; 39: 369–71PubMedCrossRefGoogle Scholar
  13. 13.
    Dahl ML, Bertilsson L, Nordin C. Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996; 123: 315–9CrossRefGoogle Scholar
  14. 14.
    Mellstrom B, Bertilsson L, Sawe J, et al. E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 1981; 30: 189–93PubMedCrossRefGoogle Scholar
  15. 15.
    Gram LF, Brosen K, Kragh-Sorensen P, et al. Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype. Ther Drug Monit 1989; 11: 508–14PubMedCrossRefGoogle Scholar
  16. 16.
    Dalen P, Dahl ML, Bernal Ruiz ML, et al. 10-Hydroxylation of nortriptyline in White persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin Pharmacol Ther 1998; 63: 444–52PubMedCrossRefGoogle Scholar
  17. 17.
    Yue QY, Zhong ZH, Tybring G, et al. Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 1998; 64: 384–90PubMedCrossRefGoogle Scholar
  18. 18.
    Morita S, Shimoda K, Someya T, et al. Steady-state plasma levels of nortriptyline and its hydroxylated metabolites in Japanese patients: impact of CYP2D6 genotype on the hydroxylation of nortriptyline. J Clin Psychopharmacol 2000; 20: 141–9PubMedCrossRefGoogle Scholar
  19. 19.
    Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br J Clin Pharmacol 2008; 65: 134–8PubMedCrossRefGoogle Scholar
  20. 20.
    Steimer W, Zopf K, von Amelunxen S, et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376–85PubMedCrossRefGoogle Scholar
  21. 21.
    Roberts RL, Mulder RT, Joyce PR, et al. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline. Hum Psychopharmacol 2004; 19: 17–23PubMedCrossRefGoogle Scholar
  22. 22.
    van der Kuy PH, Hooymans PM. Nortriptyline intoxication induced by terbinafine. BMJ 1998; 316: 441PubMedCrossRefGoogle Scholar
  23. 23.
    Bertilsson L, Aberg-Wistedt A, Gustafsson LL, et al. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants. Ther Drug Monit 1985; 7: 478–80PubMedCrossRefGoogle Scholar
  24. 24.
    Peters II MD, Davis SK, Austin LS. Clomipramine: an antiobsessional tricyclic antidepressant. Clin Pharm 1990; 9: 165–78PubMedGoogle Scholar
  25. 25.
    Balant-Gorgia AE, Gex-Fabry M, Balant LP. Clinical pharmacokinetics of clomipramine. Clin Pharmacokinet 1991; 20: 447–62PubMedCrossRefGoogle Scholar
  26. 26.
    Nielsen KK, Flinois JP, Beaune P, et al. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 1996; 277: 1659–64PubMedGoogle Scholar
  27. 27.
    Nielsen KK, Brosen K, Hansen MG, et al. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55: 518–27PubMedCrossRefGoogle Scholar
  28. 28.
    Nielsen KK, Brosen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur J Clin Pharmacol 1992; 43:405–11PubMedCrossRefGoogle Scholar
  29. 29.
    Sindrup SH, Gram LF, Skjold T, et al. Clomipramine vs desipramine vs placebo in the treatment of diabetic neuropathy symptoms: a double-blind cross-over study. Br J Clin Pharmacol 1990; 30: 683–91PubMedCrossRefGoogle Scholar
  30. 30.
    Pinder RM, Brogden RN, Speight TM, et al. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13: 161–218PubMedCrossRefGoogle Scholar
  31. 31.
    Shu YZ, Hubbard JW, Cooper JK, et al. The identification of urinary metabolites of doxepin in patients. Drug Metab Dispos 1990; 18: 735–41PubMedGoogle Scholar
  32. 32.
    Haritos VS, Ghabrial H, Ahokas JT, et al. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000; 10: 591–603PubMedCrossRefGoogle Scholar
  33. 33.
    Hartter S, Tybring G, Friedberg T, et al. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19: 1034–7PubMedCrossRefGoogle Scholar
  34. 34.
    Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571–80PubMedCrossRefGoogle Scholar
  35. 35.
    Koski A, Ojanpera I, Sistonen J, et al. A fatal doxepin poisoning associated with a defective CYP2D6 genotype. Am J Forensic Med Pathol 2007; 28: 259–61PubMedCrossRefGoogle Scholar
  36. 36.
    Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990; 18: 346–64PubMedCrossRefGoogle Scholar
  37. 37.
    Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993; 43: 827–32PubMedGoogle Scholar
  38. 38.
    Koyama E, Chiba K, Tani M, et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997; 281: 1199–210PubMedGoogle Scholar
  39. 39.
    Brosen K, Zeugin T, Meyer UA. Role of P450IID6, the target of the sparteinedebrisoquin oxidation polymorphism, in the metabolism of imipramine. Clin Pharmacol Ther 1991; 49: 609–17PubMedCrossRefGoogle Scholar
  40. 40.
    Nakajima M, Tanaka E, Kobayashi T, et al. Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2002; 30: 636–42PubMedCrossRefGoogle Scholar
  41. 41.
    Koyama E, Kikuchi Y, Echizen H, et al. Simultaneous high-performance liquid chromatography-electrochemical detection determination of imipramine, desipramine, their 2-hydroxylated metabolites, and imipramine N-oxide in human plasma and urine: preliminary application to oxidation pharmacogenetics. Ther Drug Monit 1993; 15: 224–35PubMedCrossRefGoogle Scholar
  42. 42.
    Brosen K, Otton SV, Gram LF. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 1986; 40: 543–9PubMedCrossRefGoogle Scholar
  43. 43.
    Spina E, Steiner E, Ericsson O, et al. Hydroxylation of desmethylimipramine: dependence on the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1987; 41: 314–9PubMedCrossRefGoogle Scholar
  44. 44.
    Steiner E, Spina E. Differences in the inhibitory effect of cimetidine on desipramine metabolism between rapid and slow debrisoquin hydroxylators. Clin Pharmacol Ther 1987; 42: 278–82PubMedCrossRefGoogle Scholar
  45. 45.
    Spina E, Gitto C, Avenoso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997; 51: 395–8PubMedCrossRefGoogle Scholar
  46. 46.
    Shimoda K, Morita S, Hirokane G, et al. Metabolism of desipramine in Japanese psychiatric patients: the impact of CYP2D6 genotype on the hydroxylation of desipramine. Pharmacol Toxicol 2000; 86: 245–9PubMedCrossRefGoogle Scholar
  47. 47.
    Brosen K, Klysner R, Gram LF, et al. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679–84PubMedCrossRefGoogle Scholar
  48. 48.
    Sindrup SH, Brosen K, Gram LF. Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit 1990; 12: 445–9PubMedCrossRefGoogle Scholar
  49. 49.
    Schenk PW, van Fessem MA, Verploegh-Van Rij S, et al. Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. Mol Psychiatry 2008; 13: 597–605PubMedCrossRefGoogle Scholar
  50. 50.
    Pinder RM, Brogden RN, Speight TM, et al. Maprotiline: a review of its pharmacological properties and therapeutic efficacy in mental depressive states. Drugs 1977; 13: 321–52PubMedCrossRefGoogle Scholar
  51. 51.
    Brachtendorf L, Jetter A, Beckurts KT, et al. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90: 144–9PubMedCrossRefGoogle Scholar
  52. 52.
    Breyer-Pfaff U, Kroeker M, Winkler T, et al. Isolation and identification of hydroxylated maprotiline metabolites. Xenobiotica 1985; 15: 57–66PubMedCrossRefGoogle Scholar
  53. 53.
    Hartter S, Wetzel H, Hammes E, et al. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology (Berl) 1993; 110: 302–8CrossRefGoogle Scholar
  54. 54.
    Normann C, Lieb K, Walden J. Increased plasma concentration of maprotiline by coadministration of risperidone. J Clin Psychopharmacol 2002; 22: 92–4PubMedCrossRefGoogle Scholar
  55. 55.
    Konig F, Wolfersdorf M, Loble M, et al. Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression. Pharmacopsychiatry 1997; 30: 125–7PubMedCrossRefGoogle Scholar
  56. 56.
    Gram LF, Guentert TW, Grange S, et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995; 57: 670–7PubMedCrossRefGoogle Scholar
  57. 57.
    Firkusny L, Gleiter CH. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine. Br J Clin Pharmacol 1994; 37: 383–8PubMedCrossRefGoogle Scholar
  58. 58.
    Gastpar M. Clinical originality and new biology of trimipramine. Drugs 1989; 38 Suppl. 1: 43–8; discussion 49-50PubMedCrossRefGoogle Scholar
  59. 59.
    Bolaji OO, Coutts RT, Baker GB. Metabolism of trimipramine in vitro by human CYP2D6 isozyme. Res Commun Chem Pathol Pharmacol 1993; 82: 111–20PubMedGoogle Scholar
  60. 60.
    Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209–14PubMedCrossRefGoogle Scholar
  61. 61.
    Kirchheiner J, Muller G, Meineke I, et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459–66PubMedCrossRefGoogle Scholar
  62. 62.
    Eap CB, Laurian S, Souche A, et al. Influence of quinidine on the pharmacokinetics of trimipramine and on its effect on the waking EEG of healthy volunteers: a pilot study on two subjects. Neuropsychobiology 1992; 25: 214–20PubMedCrossRefGoogle Scholar
  63. 63.
    Leinonen E, Koponen HJ, Lepola U. Paroxetine increases serum trimipramine concentration: a report of two cases. Human Psychopharmacol Clin Exp 2004; 10: 345–7CrossRefGoogle Scholar
  64. 64.
    Musshoff F, Schmidt P, Madea B. Fatality caused by a combined trimipramine-citalopram intoxication. Forensic Sci Int 1999; 106: 125–31PubMedCrossRefGoogle Scholar
  65. 65.
    Caccia S. Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 1998; 34: 281–302PubMedCrossRefGoogle Scholar
  66. 66.
    Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28PubMedCrossRefGoogle Scholar
  67. 67.
    Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1–21PubMedCrossRefGoogle Scholar
  68. 68.
    Fogelman SM, Schmider J, Venkatakrishnan K, et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20: 480–90PubMedCrossRefGoogle Scholar
  69. 69.
    Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46: 281–90PubMedCrossRefGoogle Scholar
  70. 70.
    Olesen OV, Linnet K. Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 1999; 59: 298–309PubMedCrossRefGoogle Scholar
  71. 71.
    von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102–9Google Scholar
  72. 72.
    Herrlin K, Yasui-Furukori N, Tybring G, et al. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes. Br J Clin Pharmacol 2003; 56: 415–21PubMedCrossRefGoogle Scholar
  73. 73.
    Peters EJ, Slager SL, Kraft JB, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS ONE 2008; 3: e1872PubMedCrossRefGoogle Scholar
  74. 74.
    Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: a 5-year experience in Sweden, 1992–1997. Ther Drug Monit 2003; 25: 183–91PubMedCrossRefGoogle Scholar
  75. 75.
    Figgitt DP, McClellan KJ. Fluvoxamine: an updated review of its use in the management of adults with anxiety disorders. Drugs 2000; 60: 925–54PubMedCrossRefGoogle Scholar
  76. 76.
    Wilde MI, Plosker GL, Benfield P. Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895–924PubMedCrossRefGoogle Scholar
  77. 77.
    Spigset O, Granberg K, Hagg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol 1998; 45: 257–63PubMedCrossRefGoogle Scholar
  78. 78.
    Perucca E, Gatti G, Spina E. Clinical pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1994; 27: 175–90PubMedCrossRefGoogle Scholar
  79. 79.
    Spigset O, Axelsson S, Norstrom A, et al. The major fluvoxamine metabolite in urine is formed by CYP2D6. Eur J Clin Pharmacol 2001; 57: 653–8PubMedCrossRefGoogle Scholar
  80. 80.
    DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997; 58 Suppl. 5: 7–14PubMedGoogle Scholar
  81. 81.
    van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 1995; 29 Suppl. 1: 1–9PubMedCrossRefGoogle Scholar
  82. 82.
    Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther 2008; 30: 1206–27PubMedCrossRefGoogle Scholar
  83. 83.
    Wagner W, Vause EW. Fluvoxamine: a review of global drug-drug interaction data. Clin Pharmacokinet 1995; 29 Suppl. 1: 26–31; discussion 31-2PubMedCrossRefGoogle Scholar
  84. 84.
    Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002; 71: 141–52PubMedCrossRefGoogle Scholar
  85. 85.
    Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochrome P4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006; 31: 825–31PubMedCrossRefGoogle Scholar
  86. 86.
    Kirchheiner J, Brosen K, Dahl ML, et al. CYP2D6 and CYP2C19 genotypebased dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104: 173–92PubMedCrossRefGoogle Scholar
  87. 87.
    Mandrioli R, Forti GC, Raggi MA. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome P450. Curr Drug Metab 2006; 7: 127–33PubMedCrossRefGoogle Scholar
  88. 88.
    Margolis JM, O’Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 2000; 28: 1187–91PubMedGoogle Scholar
  89. 89.
    Ring BJ, Eckstein JA, Gillespie JS, et al. Identification of the human cytochromes P450 responsible for in vitro formation of R- and S-norfluoxetine. J Pharmacol Exp Ther 2001; 297: 1044–50PubMedGoogle Scholar
  90. 90.
    Hamelin BA, Turgeon J, Vallee F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996; 60: 512–21PubMedCrossRefGoogle Scholar
  91. 91.
    Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. Pharmacogenetics 1999; 9: 55–60PubMedCrossRefGoogle Scholar
  92. 92.
    Scordo MG, Spina E, Dahl ML, et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296–301PubMedCrossRefGoogle Scholar
  93. 93.
    Stedman CA, Begg EJ, Kennedy MA, et al. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia. Hum Psychopharmacol 2002; 17: 187–90PubMedCrossRefGoogle Scholar
  94. 94.
    Gunasekara NS, Noble S, Benfield P. Paroxetine: an update of its pharmacology and therapeutic use in depression and a review of its use in other disorders. Drugs 1998; 55: 85–120PubMedCrossRefGoogle Scholar
  95. 95.
    Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992; 33: 521–3PubMedCrossRefGoogle Scholar
  96. 96.
    Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278–87PubMedCrossRefGoogle Scholar
  97. 97.
    Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288–95PubMedCrossRefGoogle Scholar
  98. 98.
    Ozdemir V, Tyndale RF, Reed K, et al. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. J Clin Psychopharmacol 1999; 19: 472–5PubMedCrossRefGoogle Scholar
  99. 99.
    Lam YW, Gaedigk A, Ereshefsky L, et al. CYP2D6 inhibition by selective serotonin reuptake inhibitors: analysis of achievable steady-state plasma concentrations and the effect of ultrarapid metabolism at CYP2D6. Pharmacotherapy 2002; 22: 1001–6PubMedCrossRefGoogle Scholar
  100. 100.
    Charlier C, Broly F, Lhermitte M, et al. Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738–42PubMedCrossRefGoogle Scholar
  101. 101.
    Zourkova A, Hadasova E. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment. J Sex Marital Ther 2002; 28: 451–61PubMedCrossRefGoogle Scholar
  102. 102.
    Murphy Jr GM, Kremer C, Rodrigues S, et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830–5PubMedCrossRefGoogle Scholar
  103. 103.
    Tanaka M, Kobayashi D, Murakami Y, et al. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea. Int J Neuropsychopharmacol 2008; 11: 261–7PubMedCrossRefGoogle Scholar
  104. 104.
    Pinder RM, Van Delft AM. The potential therapeutic role of the enantiomers and metabolites of mianserin. Br J Clin Pharmacol 1983; 15 Suppl. 2: 269–76SCrossRefGoogle Scholar
  105. 105.
    Delbressine LP, Moonen ME, Kaspersen FM, et al. Biotransformation of mianserin in laboratory animals and man. Xenobiotica 1992; 22: 227–36PubMedCrossRefGoogle Scholar
  106. 106.
    Stormer E, von Moltke LL, Shader RI, et al. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168–75PubMedGoogle Scholar
  107. 107.
    Koyama E, Chiba K, Tani M, et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278: 21–30PubMedGoogle Scholar
  108. 108.
    Dahl ML, Tybring G, Elwin CE, et al. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism. Clin Pharmacol Ther 1994; 56: 176–83PubMedCrossRefGoogle Scholar
  109. 109.
    Yasui N, Tybring G, Otani K, et al. Effects of thioridazine, an inhibitor of CYP2D6, on the steady-state plasma concentrations of the enantiomers of mianserin and its active metabolite, desmethylmianserin, in depressed Japanese patients. Pharmacogenetics 1997; 7: 369–74PubMedCrossRefGoogle Scholar
  110. 110.
    Sindrup SH, Tuxen C, Gram LF, et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. Eur J Clin Pharmacol 1992; 43: 251–5PubMedCrossRefGoogle Scholar
  111. 111.
    Tacke U, Leinonen E, Lillsunde P, et al. Debrisoquine hydroxylation phenotypes of patients with high versus low to normal serum antidepressant concentrations. J Clin Psychopharmacol 1992; 12: 262–7PubMedCrossRefGoogle Scholar
  112. 112.
    Begg EJ, Sharman JR, Kidd JE, et al. Variability in the elimination of mianserin in elderly patients. Br J Clin Pharmacol 1989; 27: 445–51PubMedCrossRefGoogle Scholar
  113. 113.
    Mihara K, Otani K, Tybring G, et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997; 17: 467–71PubMedCrossRefGoogle Scholar
  114. 114.
    Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001; 7: 249–64PubMedCrossRefGoogle Scholar
  115. 115.
    Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461–74PubMedCrossRefGoogle Scholar
  116. 116.
    Delbressine LP, Moonen ME, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 1998; 15: 45–55PubMedCrossRefGoogle Scholar
  117. 117.
    Grasmader K, Verwohlt PL, Kuhn KU, et al. Population pharmacokinetic analysis of mirtazapine. Eur J Clin Pharmacol 2004; 60: 473–80PubMedCrossRefGoogle Scholar
  118. 118.
    Kirchheiner J, Henckel HB, Meineke I, et al. Impact of the CYP2D6 ultrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers. J Clin Psychopharmacol 2004; 24: 647–52PubMedCrossRefGoogle Scholar
  119. 119.
    Brockmoller J, Meineke I, Kirchheiner J. Pharmacokinetics of mirtazapine: enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects. Clin Pharmacol Ther 2007; 81: 699–707PubMedCrossRefGoogle Scholar
  120. 120.
    Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995; 49: 280–94PubMedCrossRefGoogle Scholar
  121. 121.
    Ellingrod VL, Perry PJ. Venlafaxine: a heterocyclic antidepressant. Am J Hosp Pharm 1994; 51: 3033–46PubMedGoogle Scholar
  122. 122.
    Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996; 41: 149–56PubMedCrossRefGoogle Scholar
  123. 123.
    Lindh JD, Annas A, Meurling L, et al. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. Eur J Clin Pharmacol 2003; 59: 401–6PubMedCrossRefGoogle Scholar
  124. 124.
    Lessard E, Yessine MA, Hamelin BA, et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 1999; 9: 435–43PubMedCrossRefGoogle Scholar
  125. 125.
    Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202–8PubMedCrossRefGoogle Scholar
  126. 126.
    Fukuda T, Nishida Y, Zhou Q, et al. The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population. Eur J Clin Pharmacol 2000; 56: 175–80PubMedCrossRefGoogle Scholar
  127. 127.
    Eap CB, Lessard E, Baumann P, et al. Role of CYP2D6 in the stereoselective disposition of venlafaxine in humans. Pharmacogenetics 2003; 13: 39–47PubMedCrossRefGoogle Scholar
  128. 128.
    Whyte EM, Romkes M, Mulsant BH, et al. CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. Int J Geriatr Psychiatry 2006; 21: 542–9PubMedCrossRefGoogle Scholar
  129. 129.
    Shams ME, Arneth B, Hiemke C, et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31:493–502PubMedCrossRefGoogle Scholar
  130. 130.
    Hermann M, Hendset M, Fosaas K, et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008; 64: 483–7PubMedCrossRefGoogle Scholar
  131. 131.
    McAlpine DE, O’Kane DJ, Black JL, et al. Cytochrome P450 2D6 genotype variation and venlafaxine dosage. Mayo Clin Proc 2007; 82: 1065–8PubMedCrossRefGoogle Scholar
  132. 132.
    Xu ZH, Wang W, Zhao XJ, et al. Evidence for involvement of polymorphic CYP2C19 and 2C9 in the N-demethylation of sertraline in human livermicrosomes. Br J Clin Pharmacol 1999; 48: 416–23PubMedCrossRefGoogle Scholar
  133. 133.
    Bertilsson L, Mellstrom B, Sjokvist F, et al. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: clinical implications. Lancet 1981; 1: 560–1PubMedCrossRefGoogle Scholar
  134. 134.
    Bluhm RE, Wilkinson GR, Shelton R, et al. Genetically determined drugmetabolizing activity and desipramine-associated cardiotoxicity: a case report. Clin Pharmacol Ther 1993; 53: 89–95PubMedCrossRefGoogle Scholar
  135. 135.
    Bertilsson L, Dahl ML, Sjoqvist F, et al. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 1993; 341:63PubMedCrossRefGoogle Scholar
  136. 136.
    Rau T, Wohlleben G, Wuttke H, et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants. A pilot study. Clin Pharmacol Ther 2004; 75: 386–93PubMedCrossRefGoogle Scholar
  137. 137.
    Kawanishi C, Lundgren S, Agren H, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 2004; 59: 803–7PubMedCrossRefGoogle Scholar
  138. 138.
    Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329–36PubMedGoogle Scholar
  139. 139.
    Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol 2008; 65: 558–64PubMedCrossRefGoogle Scholar
  140. 140.
    Kwadijk-de Gijsel S, Bijl MJ, Visser LE, et al. Variation in the CYP2D6 gene is associated with a lower serum sodium concentration in patients on antidepressants. Br J Clin Pharmacol 2009; 68: 221–5PubMedCrossRefGoogle Scholar
  141. 141.
    Seeringer A, Kirchheiner J. Pharmacogenetics-guided dose modifications of antidepressants. Clin Lab Med 2008; 28: 619–26PubMedCrossRefGoogle Scholar
  142. 142.
    Lieberman JA, Bymaster FP, Meltzer HY, et al. Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. Pharmacol Rev 2008; 60: 358–403PubMedCrossRefGoogle Scholar
  143. 143.
    Worrel JA, Marken PA, Beckman SE, et al. Atypical antipsychotic agents: a critical review. Am J Health Syst Pharm 2000; 57: 238–55PubMedGoogle Scholar
  144. 144.
    Vohora D. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Curr Opin Investig Drugs 2007; 8: 531–8PubMedGoogle Scholar
  145. 145.
    Moller HJ. Risperidone: a review. Expert Opin Pharmacother 2005; 6: 803–18PubMedCrossRefGoogle Scholar
  146. 146.
    Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008; 68: 2269–92PubMedCrossRefGoogle Scholar
  147. 147.
    Gardiner SJ, Begg EJ. Pharmacogenetics drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006; 58: 521–90PubMedCrossRefGoogle Scholar
  148. 148.
    Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenom J 2005; 5: 6–13CrossRefGoogle Scholar
  149. 149.
    Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. Curr Drug Metab 2008; 9: 738–84PubMedCrossRefGoogle Scholar
  150. 150.
    Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004; 64: 1715–36PubMedCrossRefGoogle Scholar
  151. 151.
    Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400–11PubMedCrossRefGoogle Scholar
  152. 152.
    Molden E, Lunde H, Lunder N, et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28: 744–9PubMedCrossRefGoogle Scholar
  153. 153.
    Kubo M, Koue T, Inaba A, et al. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005; 20: 55–64PubMedCrossRefGoogle Scholar
  154. 154.
    Kim JR, Seo HB, Cho JY, et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008; 66: 802–10PubMedCrossRefGoogle Scholar
  155. 155.
    Koue T, Kubo M, Funaki T, et al. Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. Biol Pharm Bull 2007; 30: 2154–8PubMedCrossRefGoogle Scholar
  156. 156.
    Kubo M, Koue T, Maune H, et al. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007; 22: 358–66PubMedCrossRefGoogle Scholar
  157. 157.
    Hendset M, Hermann M, Lunde H, et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63: 1147–51PubMedCrossRefGoogle Scholar
  158. 158.
    Oosterhuis M, Van De Kraats G, Tenback D. Safety of aripiprazole: high serum levels in a CYP2D6 mutated patient. Am J Psychiatry 2007; 164: 175PubMedCrossRefGoogle Scholar
  159. 159.
    Waade RB, Christensen H, Rudberg I, et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31: 233–8PubMedCrossRefGoogle Scholar
  160. 160.
    Hartmann F, Gruenke LD, Craig JC, et al. Chlorpromazine metabolism in extracts of liver and small intestine from guinea pig and from man. Drug Metab Dispos 1983; 11: 244–8PubMedGoogle Scholar
  161. 161.
    Yoshii K, Kobayashi K, Tsumuji M, et al. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67: 175–84PubMedCrossRefGoogle Scholar
  162. 162.
    Muralidharan G, Cooper JK, Hawes EM, et al. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine. Eur J Clin Pharmacol 1996; 50: 121–8PubMedCrossRefGoogle Scholar
  163. 163.
    Sunwoo YE, Ryu J, Jung H, et al. Disposition of chlorpromazine in Korean healthy subjects with CYP2D6 wild-type and *10B mutation [abstract]. Clin Pharmacol Ther 2004; 73: PII–146Google Scholar
  164. 164.
    Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37: 435–56PubMedCrossRefGoogle Scholar
  165. 165.
    Yatham LN. The role of novel antipsychotics in bipolar disorders. J Clin Psychiatry 2002; 63: 10–4PubMedCrossRefGoogle Scholar
  166. 166.
    Tateishi T, Watanabe M, Kumai T, et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67: 2913–20PubMedCrossRefGoogle Scholar
  167. 167.
    Kudo S, Odomi M. Involvement of human cytochrome P450 3A4 in reduced haloperidol oxidation. Eur J Clin Pharmacol 1998; 54: 253–9PubMedCrossRefGoogle Scholar
  168. 168.
    Pan LP, De Vriendt C, Belpaire FM. In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 1998; 8: 383–9PubMedCrossRefGoogle Scholar
  169. 169.
    Kim YH, Cha IJ, Shim JC, et al. Effect of rifampin on the plasma concentration and the clinical effect of haloperidol concomitantly administered to schizophrenic patients. J Clin Psychopharmacol 1996; 16: 247–52PubMedCrossRefGoogle Scholar
  170. 170.
    Avenoso A, Spina E, Campo G, et al. Interaction between fluoxetine and haloperidol: pharmacokinetic and clinical implications. Pharmacol Res 1997; 35: 335–9PubMedGoogle Scholar
  171. 171.
    Vandel S, Bertschy G, Baumann P, et al. Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients. Pharmacol Res 1995; 31: 347–53PubMedCrossRefGoogle Scholar
  172. 172.
    Ulrich S, Wurthmann C, Brosz M, et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227–63PubMedCrossRefGoogle Scholar
  173. 173.
    Lane HY, Hu OY, Jann MW, et al. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatry Res 1997; 69: 105–11PubMedCrossRefGoogle Scholar
  174. 174.
    Llerena A, Alm C, Dahl ML, et al. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 1992; 14: 92–7PubMedCrossRefGoogle Scholar
  175. 175.
    Llerena A, Dahl ML, Ekqvist B, et al. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14: 261–4PubMedCrossRefGoogle Scholar
  176. 176.
    Nyberg S, Farde L, Halldin C, et al. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry 1995; 152: 173–8PubMedGoogle Scholar
  177. 177.
    Brockmoller J, Kirchheiner J, Schmider J, et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438–52PubMedCrossRefGoogle Scholar
  178. 178.
    Panagiotidis G, Arthur HW, Lindh JD, et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007; 29: 417–22PubMedCrossRefGoogle Scholar
  179. 179.
    Suzuki A, Otani K, Mihara K, et al. Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics 1997; 7: 415–8PubMedCrossRefGoogle Scholar
  180. 180.
    Mihara K, Suzuki A, Kondo T, et al. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther 1999; 65: 291–4PubMedCrossRefGoogle Scholar
  181. 181.
    Roh HK, Chung JY, Oh DY, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265–71PubMedCrossRefGoogle Scholar
  182. 182.
    Park JY, Shon JH, Kim KA, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol 2006; 26: 135–42PubMedCrossRefGoogle Scholar
  183. 183.
    Shimoda K, Morita S, Yokono A, et al. CYP2D6*10 alleles are not the determinant of the plasma haloperidol concentrations in Asian patients. Ther Drug Monit 2000; 22: 392–6PubMedCrossRefGoogle Scholar
  184. 184.
    Ohnuma T, Shibata N, Matsubara Y, et al. Haloperidol plasma concentration in Japanese psychiatric subjects with gene duplication of CYP2D6. Br J Clin Pharmacol 2003; 56: 315–20PubMedCrossRefGoogle Scholar
  185. 185.
    Pan L, Vander Stichele R, Rosseel MT, et al. Effects of smoking, CYP2D6 genotype, and concomitant drug intake on the steady state plasma concentrations of haloperidol and reduced haloperidol in schizophrenic inpatients. Ther Drug Monit 1999; 21: 489–97PubMedCrossRefGoogle Scholar
  186. 186.
    Someya T, Suzuki Y, Shimoda K, et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin Neurosci 1999; 53: 593–7PubMedCrossRefGoogle Scholar
  187. 187.
    Hartung B, Wada M, Laux G, et al. Perphenazine for schizophrenia. Cochrane Database Syst Rev 2005; (1): CD003443PubMedGoogle Scholar
  188. 188.
    Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50: 563–71PubMedCrossRefGoogle Scholar
  189. 189.
    Bertilsson L, Dahl ML, Ekqvist B, et al. Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol Ser 1993; 10: 230–7PubMedGoogle Scholar
  190. 190.
    Dahl-Puustinen ML, Liden A, Alm C, et al. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78–81PubMedCrossRefGoogle Scholar
  191. 191.
    Linnet K, Wiborg O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41–7PubMedCrossRefGoogle Scholar
  192. 192.
    Jerling M, Dahl ML, Aberg-Wistedt A, et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423–8PubMedCrossRefGoogle Scholar
  193. 193.
    Ozdemir V, Bertilsson L, Miura J, et al. CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited. Pharmacogenet Genomics 2007; 17: 339–47PubMedCrossRefGoogle Scholar
  194. 194.
    Aklillu E, Kalow W, Endrenyi L, et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17: 989–93PubMedCrossRefGoogle Scholar
  195. 195.
    Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Psychopharmacol 2008; 22: 46–55PubMedCrossRefGoogle Scholar
  196. 196.
    O’Keane V. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008; 22: 70–5PubMedCrossRefGoogle Scholar
  197. 197.
    Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008; 22: 98–103PubMedCrossRefGoogle Scholar
  198. 198.
    Molitch ME. Drugs and prolactin. Pituitary 2008; 11: 209–18PubMedCrossRefGoogle Scholar
  199. 199.
    Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64: 2291–314PubMedCrossRefGoogle Scholar
  200. 200.
    Yu AM, Idle JR, Byrd LG, et al. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 2003; 13: 173–81PubMedCrossRefGoogle Scholar
  201. 201.
    Ozdemir V, Naranjo CA, Herrmann N, et al. Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334–47PubMedCrossRefGoogle Scholar
  202. 202.
    Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31: 327–31PubMedGoogle Scholar
  203. 203.
    Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs 2005; 19: 429–44PubMedCrossRefGoogle Scholar
  204. 204.
    Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs 1994; 48: 253–73PubMedCrossRefGoogle Scholar
  205. 205.
    Mannens G, Huang ML, Meuldermans W, et al. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Dispos 1993; 21: 1134–41PubMedGoogle Scholar
  206. 206.
    Yasui-Furukori N, Hidestrand M, Spina E, et al. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos 2001; 29: 1263–8PubMedGoogle Scholar
  207. 207.
    Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: effect of comedication with carbamazepine or valproate. Ther Drug Monit 2000; 22: 481–5PubMedCrossRefGoogle Scholar
  208. 208.
    Jung SM, Kim KA, Cho HK, et al. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients. Clin Pharmacol Ther 2005; 78: 520–8PubMedCrossRefGoogle Scholar
  209. 209.
    Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124: 57–73CrossRefGoogle Scholar
  210. 210.
    Spina E, Avenoso A, Facciola G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine. Ther Drug Monit 2001; 23: 223–7PubMedCrossRefGoogle Scholar
  211. 211.
    Mannheimer B, Bahr CV, Pettersson H, et al. Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit. Epub 2008 Aug 23Google Scholar
  212. 212.
    Scordo MG, Spina E, Facciola G, et al. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 1999; 147: 300–5CrossRefGoogle Scholar
  213. 213.
    Bondolfi G, Eap CB, Bertschy G, et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 2002; 35: 50–6PubMedCrossRefGoogle Scholar
  214. 214.
    Olesen OV, Licht RW, Thomsen E, et al. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 1998; 20: 380–4PubMedCrossRefGoogle Scholar
  215. 215.
    Nyberg S, Dahl ML, Halldin C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 1995; 119: 345–8CrossRefGoogle Scholar
  216. 216.
    Roh HK, Kim CE, Chung WG, et al. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 2001; 57: 671–5PubMedCrossRefGoogle Scholar
  217. 217.
    Guzey C, Aamo T, Spigset O. Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry 2000; 61: 600–1PubMedCrossRefGoogle Scholar
  218. 218.
    De Leon J, Susce MT, Pan RM, et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15–27PubMedCrossRefGoogle Scholar
  219. 219.
    Wojcikowski J, Maurel P, Daniel WA. Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab Dispos 2006; 34: 471–6PubMedGoogle Scholar
  220. 220.
    Llerena A, Berecz R, de la Rubia A, et al. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit 2000; 22: 397–401PubMedCrossRefGoogle Scholar
  221. 221.
    Berecz R, de la Rubia A, Dorado P, et al. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol 2003; 59: 45–50PubMedGoogle Scholar
  222. 222.
    Eap CB, Guentert TW, Schaublin-Loidl M, et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322–31PubMedCrossRefGoogle Scholar
  223. 223.
    Llerena A, Berecz R, de la Rubia A, et al. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol 2002; 16: 361–4PubMedCrossRefGoogle Scholar
  224. 224.
    von Bahr C, Movin G, Nordin C, et al. Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1991; 49: 234–40CrossRefGoogle Scholar
  225. 225.
    Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev 2005; (4): CD005474PubMedGoogle Scholar
  226. 226.
    Dahl ML, Ekqvist B, Widen J, et al. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 1991; 84: 99–102PubMedCrossRefGoogle Scholar
  227. 227.
    Linnet K, Wiborg O. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit 1996; 18: 629–34PubMedCrossRefGoogle Scholar
  228. 228.
    Jaanson P, Marandi T, Kiivet RA, et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002; 162: 67–73CrossRefGoogle Scholar
  229. 229.
    Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996; 276: 658–66PubMedGoogle Scholar
  230. 230.
    Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823–32PubMedCrossRefGoogle Scholar
  231. 231.
    Schaber G, Wiatr G, Wachsmuth H, et al. Isolation and identification of clozapine metabolites in patient urine. Drug Metab Dispos 2001; 29: 923–31PubMedGoogle Scholar
  232. 232.
    Breyer-Pfaff U, Wachsmuth H. Tertiary N-glucuronides of clozapine and its metabolite desmethylclozapine in patient urine. Drug Metab Dispos 2001; 29: 1343–8PubMedGoogle Scholar
  233. 233.
    Hagg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001; 57: 493–7PubMedCrossRefGoogle Scholar
  234. 234.
    Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003; 23: 119–27PubMedCrossRefGoogle Scholar
  235. 235.
    Melkersson KI, Scordo MG, Gunes A, et al. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007; 68: 697–704PubMedCrossRefGoogle Scholar
  236. 236.
    Dettling M, Sachse C, Muller-Oerlinghausen B, et al. Clozapine-induced agranulocytosis and hereditary polymorphisms of clozapine metabolizing enzymes: no association with myeloperoxidase and cytochrome P4502D6. Pharmacopsychiatry 2000; 33: 218–20PubMedCrossRefGoogle Scholar
  237. 237.
    Uehlinger C, Crettol S, Chassot P, et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27: 273–8PubMedCrossRefGoogle Scholar
  238. 238.
    Plesnicar BK, Zalar B, Breskvar K, et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20: 829–33PubMedCrossRefGoogle Scholar
  239. 239.
    Chou WH, Yan FX, de Leon J, et al. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness. J Clin Psychopharmacol 2000; 20: 246–51PubMedCrossRefGoogle Scholar
  240. 240.
    Dahl ML. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41: 453–70PubMedCrossRefGoogle Scholar
  241. 241.
    Otani K, Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 2000; 22: 118–21PubMedCrossRefGoogle Scholar
  242. 242.
    Patsopoulos NA, Ntzani EE, Zintzaras E, et al. CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 2005; 15: 151–8PubMedCrossRefGoogle Scholar
  243. 243.
    Sjoqvist F, Eliasson E. The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther 2007; 81: 899–902PubMedCrossRefGoogle Scholar
  244. 244.
    Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719–39PubMedCrossRefGoogle Scholar
  245. 245.
    Spaldin V, Madden S, Pool WF, et al. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38: 15–22PubMedCrossRefGoogle Scholar
  246. 246.
    Barner EL, Gray SL. Donepezil use in Alzheimer disease. Ann Pharmacother 1998; 32: 70–7PubMedCrossRefGoogle Scholar
  247. 247.
    Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661–8PubMedCrossRefGoogle Scholar
  248. 248.
    Seltzer B. Donepezil: an update. Expert Opin Pharmacother 2007; 8: 1011–23PubMedCrossRefGoogle Scholar
  249. 249.
    Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62: 721–6PubMedCrossRefGoogle Scholar
  250. 250.
    Whitehead A, Perdomo C, Pratt RD, et al. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer’s disease: a metaanalysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry 2004; 19: 624–33PubMedCrossRefGoogle Scholar
  251. 251.
    Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol 1998; 46 Suppl. 1: 19–24PubMedCrossRefGoogle Scholar
  252. 252.
    Cacabelos R, Llovo R, Fraile C, et al. Pharmacogenetic aspects of therapy with cholinesterase inhibitors: the role of CYP2D6 in Alzheimer’s disease pharmacogenetics. Curr Alzheimer Res 2007; 4: 479–500PubMedCrossRefGoogle Scholar
  253. 253.
    Pilotto A, Franceschi M, D’Onofrio G, et al. Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. Neurology 2009; 73: 761–7PubMedCrossRefGoogle Scholar
  254. 254.
    Gaedigk A, Ryder DL, Bradford LD, et al. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin Chem 2003; 49: 1008–11PubMedCrossRefGoogle Scholar
  255. 255.
    Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol 2007; 6: 782–92PubMedCrossRefGoogle Scholar
  256. 256.
    Westra P, van Thiel MJ, Vermeer GA, et al. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986; 58: 1303–7PubMedCrossRefGoogle Scholar
  257. 257.
    Mannens GS, Snel CA, Hendrickx J, et al. The metabolism and excretion of galantamine in rats, dogs, and humans. Drug Metab Dispos 2002; 30: 553–63PubMedCrossRefGoogle Scholar
  258. 258.
    Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2004; 61: 2391–9PubMedGoogle Scholar
  259. 259.
    Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs 2004; 64: 205–22PubMedCrossRefGoogle Scholar
  260. 260.
    Ring BJ, Gillespie JS, Eckstein JA, et al. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab Dispos 2002; 30: 319–23PubMedCrossRefGoogle Scholar
  261. 261.
    Farid NA, Bergstrom RF, Ziege EA, et al. Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. J Clin Pharmacol 1985; 25: 296–301PubMedGoogle Scholar
  262. 262.
    Paulzen M, Clement HW, Grunder G. Enhancement of atomoxetine serum levels by co-administration of paroxetine. Int J Neuropsychopharmacol 2008; 11:289–91PubMedCrossRefGoogle Scholar
  263. 263.
    Sauer JM, Ponsler GD, Mattiuz EL, et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab Dispos 2003; 31: 98–107PubMedCrossRefGoogle Scholar
  264. 264.
    Cui YM, Teng CH, Pan AX, et al. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. Br J Clin Pharmacol 2007; 64: 445–9PubMedCrossRefGoogle Scholar
  265. 265.
    Shen H, He MM, Liu H, et al. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab Dispos 2007; 35: 1292–300PubMedCrossRefGoogle Scholar
  266. 266.
    Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242–51PubMedCrossRefGoogle Scholar
  267. 267.
    Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol 2008; 18: 79–86PubMedCrossRefGoogle Scholar
  268. 268.
    Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001; 108: E83PubMedCrossRefGoogle Scholar
  269. 269.
    Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry 2002; 63 Suppl. 12: 50–5PubMedGoogle Scholar
  270. 270.
    Tamayo JM, Pumariega A, Rothe EM, et al. Latino versus Caucasian response to atomoxetine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2008; 18: 44–53PubMedCrossRefGoogle Scholar
  271. 271.
    Baskys A, Hou AC. Vascular dementia: pharmacological treatment approaches and perspectives. Clin Interv Aging 2007; 2: 327–35PubMedGoogle Scholar
  272. 272.
    Winblad B, Fioravanti M, Dolezal T, et al. Therapeutic use of nicergoline. Clin Drug Investig 2008; 28: 533–52PubMedCrossRefGoogle Scholar
  273. 273.
    Arcamone F, Glasser AG, Grafnetterova J, et al. Studies on the metabolism of ergoline derivatives: metabolism of nicergoline in man and in animals. Biochem Pharmacol 1972; 21: 2205–13PubMedCrossRefGoogle Scholar
  274. 274.
    Bottiger Y, Dostert P, Benedetti MS, et al. Involvement of CYP2D6 but not CYP2C19 in nicergoline metabolism in humans. Br J Clin Pharmacol 1996; 42:707–11PubMedCrossRefGoogle Scholar
  275. 275.
    Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol 2001; 19: 312–8PubMedCrossRefGoogle Scholar
  276. 276.
    Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998; 26: 289–93PubMedGoogle Scholar
  277. 277.
    Nilvebrant L, Gillberg PG, Sparf B. Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol 1997; 81: 169–72PubMedCrossRefGoogle Scholar
  278. 278.
    Brynne N, Forslund C, Hallen B, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol 1999; 48: 564–72PubMedCrossRefGoogle Scholar
  279. 279.
    Brynne N, Dalen P, Alvan G, et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998; 63: 529–39PubMedCrossRefGoogle Scholar
  280. 280.
    Brynne N, Bottiger Y, Hallen B, et al. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol 1999; 47: 145–50PubMedCrossRefGoogle Scholar
  281. 281.
    Brynne N, Svanstrom C, Aberg-Wistedt A, et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol 1999; 48: 553–63PubMedCrossRefGoogle Scholar
  282. 282.
    Olsson B, Szamosi J. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder. Clin Pharmacokinet 2001; 40: 135–43PubMedCrossRefGoogle Scholar
  283. 283.
    Olsson B, Szamosi J. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet 2001; 40: 227–35PubMedCrossRefGoogle Scholar
  284. 284.
    Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008; 358: 2482–94PubMedCrossRefGoogle Scholar
  285. 285.
    Schwartzberg LS. Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy? Oncology (Williston Park) 2007; 21: 946–53; discussion 954, 959, 962 passimGoogle Scholar
  286. 286.
    Aapro M. 5-HT3-receptor antagonists in the management of nausea and vomiting in cancer and cancer treatment. Oncology 2005; 69: 97–109PubMedCrossRefGoogle Scholar
  287. 287.
    Aapro M, Blower P. 5-Hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents? Cancer 2005; 104: 1–18PubMedCrossRefGoogle Scholar
  288. 288.
    Evangelista S. Eziopitant: Pfizer. Curr Opin Investig Drugs 2001; 2: 1441–3PubMedGoogle Scholar
  289. 289.
    Fischer V, Baldeck JP, Tse FL. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans. Drug Metab Dispos 1992; 20: 603–7PubMedGoogle Scholar
  290. 290.
    Kutz K. Pharmacology, toxicology and human pharmacokinetics of tropisetron. Ann Oncol 1993; 4 Suppl. 3: 15–18PubMedCrossRefGoogle Scholar
  291. 291.
    Fischer V, Vickers AE, Heitz F, et al. The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron. Drug Metab Dispos 1994; 22: 269–74PubMedGoogle Scholar
  292. 292.
    Sanwald P, David M, Dow J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of dolasetron: comparison with other indole-containing 5-HT3 antagonists. Drug Metab Dispos 1996; 24: 602–9PubMedGoogle Scholar
  293. 293.
    Obach RS. Cytochrome P450-catalyzed metabolism of ezlopitant alkene (CJ-12,458), a pharmacologically active metabolite of ezlopitant: enzyme kinetics and mechanism of an alkene hydration reaction. Drug Metab Dispos 2001; 29: 1057–67PubMedGoogle Scholar
  294. 294.
    Desta Z, Wu GM, Morocho AM, et al. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos 2002; 30: 336–43PubMedCrossRefGoogle Scholar
  295. 295.
    Gregory RE, Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 173–89PubMedCrossRefGoogle Scholar
  296. 296.
    Obach RS. Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos 2000; 28: 1069–76PubMedGoogle Scholar
  297. 297.
    Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004; 32: 1287–92PubMedCrossRefGoogle Scholar
  298. 298.
    Balfour JA, Goa KL. Dolasetron: a review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. Drugs 1997; 54: 273–98PubMedCrossRefGoogle Scholar
  299. 299.
    Reith MK, Sproles GD, Cheng LK. Human metabolism of dolasetron mesylate, a 5-HT3 receptor antagonist. Drug Metab Dispos 1995; 23: 806–12PubMedGoogle Scholar
  300. 300.
    Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127–33PubMedCrossRefGoogle Scholar
  301. 301.
    Milne RJ, Heel RC. Ondansetron: therapeutic use as an antiemetic. Drugs 1991; 41: 574–95PubMedCrossRefGoogle Scholar
  302. 302.
    Ashforth EI, Palmer JL, Bye A, et al. The pharmacokinetics of ondansetron after intravenous injection in healthy volunteers phenotyped as poor or extensive metabolisers of debrisoquine. Br J Clin Pharmacol 1994; 37: 389–91PubMedCrossRefGoogle Scholar
  303. 303.
    Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting: do CYP2D6 allele copy number and polymorphisms affect the success or failure of ondansetron prophylaxis? Anesthesiology 2005; 102: 543–9PubMedCrossRefGoogle Scholar
  304. 304.
    Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297–315PubMedCrossRefGoogle Scholar
  305. 305.
    Lee CR, Plosker GL, McTavish D. Tropisetron: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic. Drugs 1993; 46: 925–43PubMedCrossRefGoogle Scholar
  306. 306.
    Firkusny L, Kroemer HK, Eichelbaum M. In vitro characterization of cytochrome P450 catalysed metabolism of the antiemetic tropisetron. Biochem Pharmacol 1995; 49: 1777–84PubMedCrossRefGoogle Scholar
  307. 307.
    Kim MK, Cho JY, Lim HS, et al. Effect of the CYP2D6 genotype on the pharmacokinetics of tropisetron in healthy Korean subjects. Eur J Clin Pharmacol 2003; 59: 111–6PubMedGoogle Scholar
  308. 308.
    Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805–11PubMedCrossRefGoogle Scholar
  309. 309.
    Oppenheimer JJ, Casale TB. Next generation antihistamines: therapeutic rationale, accomplishments and advances. Expert Opin Investig Drugs 2002; 11: 807–17PubMedCrossRefGoogle Scholar
  310. 310.
    Devillier P, Roche N, Faisy C. Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 2008; 47: 217–30PubMedCrossRefGoogle Scholar
  311. 311.
    Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine: formation of descarboethoxyloratadine by CYP3A4 and CYP2D6. Biochem Pharmacol 1996; 51: 165–72PubMedCrossRefGoogle Scholar
  312. 312.
    Yumibe N, Huie K, Chen KJ, et al. Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine. Int Arch Allergy Immunol 1995; 107: 420PubMedCrossRefGoogle Scholar
  313. 313.
    Nakamura K, Yokoi T, Inoue K, et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6: 449–57PubMedCrossRefGoogle Scholar
  314. 314.
    Matsumoto S, Yamazoe Y. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine. Br J Clin Pharmacol 2001; 51: 133–42PubMedGoogle Scholar
  315. 315.
    Nakamura K, Yokoi T, Kodama T, et al. Oxidation of histamine H1 antagonist mequitazine is catalyzed by cytochrome P450 2D6 in human liver microsomes. J Pharmacol Exp Ther 1998; 284: 437–42PubMedGoogle Scholar
  316. 316.
    Jones BC, Hyland R, Ackland M, et al. Interaction of terfenadine and its primary metabolites with cytochrome P450 2D6. Drug Metab Dispos 1998; 26: 875–82PubMedGoogle Scholar
  317. 317.
    Imai T, Taketani M, Suzu T, et al. In vitro identification of the human cytochrome P-450 enzymes involved in the N-demethylation of azelastine. Drug Metab Dispos 1999; 27: 942–6PubMedGoogle Scholar
  318. 318.
    Nakajima M, Nakamura S, Tokudome S, et al. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 1999; 27: 1381–91PubMedGoogle Scholar
  319. 319.
    Goto A, Ueda K, Inaba A, et al. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull 2005; 28: 328–34PubMedCrossRefGoogle Scholar
  320. 320.
    Goto A, Adachi Y, Inaba A, et al. Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its inhibitory effect on enzyme activity. Biol Pharm Bull 2004; 27: 684–90PubMedCrossRefGoogle Scholar
  321. 321.
    Kishimoto W, Hiroi T, Sakai K, et al. Metabolism of epinastine, a histamine H1 receptor antagonist, in human liver microsomes in comparison with that of terfenadine. Res Commun Mol Pathol Pharmacol 1997; 98: 273–92PubMedGoogle Scholar
  322. 322.
    Narimatsu S, Kariya S, Isozaki S, et al. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem Biophys Res Commun 1993; 193: 1262–8PubMedCrossRefGoogle Scholar
  323. 323.
    Kariya S, Isozaki S, Uchino K, et al. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol Pharm Bull 1996; 19: 1511–4PubMedCrossRefGoogle Scholar
  324. 324.
    Akutsu T, Kobayashi K, Sakurada K, et al. Identification of human cytochrome P450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007; 35: 72–8PubMedCrossRefGoogle Scholar
  325. 325.
    He N, Zhang WQ, Shockley D, et al. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 2002; 57: 847–51PubMedCrossRefGoogle Scholar
  326. 326.
    Yasuda SU, Zannikos P, Young AE, et al. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Br J Clin Pharmacol 2002; 53: 519–25PubMedCrossRefGoogle Scholar
  327. 327.
    Tran VT, Chang RS, Snyder SH. Histamine H1. receptors identified in mammalian brain membranes with [3H]mepyramine. Proc Natl Acad Sci USA 1978; 75: 6290–4PubMedCrossRefGoogle Scholar
  328. 328.
    Peets EA, Jackson M, Symchowicz S. Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 1972; 180: 364–74PubMedGoogle Scholar
  329. 329.
    Yasuda SU, Wellstein A, Likhari P, et al. Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther 1995; 58: 210–20PubMedCrossRefGoogle Scholar
  330. 330.
    Banerji A, Long AA, Camargo CA, et al. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc 2007; 28: 418–26PubMedCrossRefGoogle Scholar
  331. 331.
    McGeer PL, Boulding JE, Gibson WC, et al. Drug-induced extrapyramidal reactions: treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA 1961; 177: 665–70PubMedCrossRefGoogle Scholar
  332. 332.
    Chang T, Okerholm RA, Glazko AJ. Identification of diphenydramine (Benadryl) metabolities in human subjects. Res Commun Chem Pathol Pharmacol 1974; 9: 391–404PubMedGoogle Scholar
  333. 333.
    Blyden GT, Greenblatt DJ, Scavone JM, et al. Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration. J Clin Pharmacol 1986; 26: 529–33PubMedGoogle Scholar
  334. 334.
    Sharma A, Hamelin BA. Classic histamine H1 receptor antagonists: a critical review of their metabolic and pharmacokinetic fate from a bird’s eye view. Curr Drug Metab 2003; 4: 105–29PubMedCrossRefGoogle Scholar
  335. 335.
    Breyer-Pfaff U, Fischer D, Winne D. Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Drug Metab Dispos 1997; 25: 340–5PubMedGoogle Scholar
  336. 336.
    Fischer D, Breyer-Pfaff U. Variability of diphenhydramine N-glucuronidation in healthy subjects. Eur J Drug Metab Pharmacokinet 1997; 22: 151–4PubMedCrossRefGoogle Scholar
  337. 337.
    Luo H, Hawes EM, McKay G, et al. N+-glucuronidation of aliphatic tertiary amines, a general phenomenon in the metabolism of H1-antihistamines in humans. Xenobiotica 1991; 21: 1281–8PubMedCrossRefGoogle Scholar
  338. 338.
    Lessard E, Yessine MA, Hamelin BA, et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J Clin Psychopharmacol 2001; 21: 175–84PubMedCrossRefGoogle Scholar
  339. 339.
    Haria M, Fitton A, Peters DH. Loratadine: a reappraisal of its pharmacological properties and therapeutic use in allergic disorders. Drugs 1994; 48: 617–37PubMedCrossRefGoogle Scholar
  340. 340.
    Ramanathan R, Reyderman L, Su AD, et al. Disposition of desloratadine in healthy volunteers. Xenobiotica 2007; 37: 770–87PubMedCrossRefGoogle Scholar
  341. 341.
    Ramanathan R, Reyderman L, Kulmatycki K, et al. Disposition of loratadine in healthy volunteers. Xenobiotica 2007; 37: 753–69PubMedCrossRefGoogle Scholar
  342. 342.
    Yin OQ, Shi XJ, Tomlinson B, et al. Effect of CYP2D6*10 allele on the pharmacokinetics of loratadine in Chinese subjects. Drug Metab Dispos 2005; 33: 1283–7PubMedCrossRefGoogle Scholar
  343. 343.
    Saruwatari J, Matsunaga M, Ikeda K, et al. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia. Eur J Clin Pharmacol 2006; 62: 995–1001PubMedCrossRefGoogle Scholar
  344. 344.
    Lotsch J. Opioid metabolites. J Pain Symptom Manage 2005; 29: S10–24PubMedCrossRefGoogle Scholar
  345. 345.
    Dayer P, Desmeules J, Leemann T, et al. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI). Biochem Biophys Res Commun 1988; 152: 411–6PubMedCrossRefGoogle Scholar
  346. 346.
    Yue QY, Sawe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol 1997; 52: 41–7PubMedCrossRefGoogle Scholar
  347. 347.
    Ohno S, Kawana K, Nakajin S. Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab Dispos 2008; 36: 688–94PubMedCrossRefGoogle Scholar
  348. 348.
    Lotsch J, Skarke C, Liefhold J, et al. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet 2004; 43: 983–1013PubMedCrossRefGoogle Scholar
  349. 349.
    Eckhardt K, Li S, Ammon S, et al. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 1998; 76: 27–33PubMedCrossRefGoogle Scholar
  350. 350.
    Poulsen L, Brosen K, Arendt-Nielsen L, et al. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289–95PubMedCrossRefGoogle Scholar
  351. 351.
    Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. J Pharmacol Exp Ther 1996; 278: 1165–74PubMedGoogle Scholar
  352. 352.
    Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics 1997; 7: 375–9PubMedCrossRefGoogle Scholar
  353. 353.
    Mikus G, Bochner F, Eichelbaum M, et al. Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism. J Pharmacol Exp Ther 1994; 268: 546–51PubMedGoogle Scholar
  354. 354.
    Mikus G, Morike K, Griese EU, et al. Relevance of deficient CYP2D6 in opiate dependence. Pharmacogenetics 1998; 8: 565–8PubMedCrossRefGoogle Scholar
  355. 355.
    Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther 2007; 81: 429–44PubMedCrossRefGoogle Scholar
  356. 356.
    Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006; 368: 704PubMedCrossRefGoogle Scholar
  357. 357.
    Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a casecontrol study. Clin Pharmacol Ther 2009; 85: 31–5PubMedCrossRefGoogle Scholar
  358. 358.
    Edwards JE, McQuay HJ, Moore RA. Single dose dihydrocodeine for acute postoperative pain. Cochrane Database Syst Rev 2000; (4): CD002760PubMedGoogle Scholar
  359. 359.
    Kirkwood LC, Nation RL, Somogyi AA. Characterization of the human cytochrome P450 enzymes involved in the metabolism of dihydrocodeine. Br J Clin Pharmacol 1997; 44: 549–55PubMedCrossRefGoogle Scholar
  360. 360.
    Fromm MF, Hofmann U, Griese EU, et al. Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans. Clin Pharmacol Ther 1995; 58: 374–82PubMedCrossRefGoogle Scholar
  361. 361.
    Wilder-Smith CH, Hufschmid E, Thormann W. The visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine: a cross-over study with extensive and quinidine-induced poor metabolizers. Br J Clin Pharmacol 1998; 45: 575–81PubMedCrossRefGoogle Scholar
  362. 362.
    Schmidt H, Vormfelde SV, Walchner-Bonjean M, et al. The role of active metabolites in dihydrocodeine effects. Int J Clin Pharmacol Ther 2003; 41: 95–106PubMedGoogle Scholar
  363. 363.
    Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991; 48: 2165–71PubMedCrossRefGoogle Scholar
  364. 364.
    Hutchinson MR, Menelaou A, Foster DJ, et al. CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes. Br J Clin Pharmacol 2004; 57: 287–97PubMedCrossRefGoogle Scholar
  365. 365.
    Otton SV, Schadel M, Cheung SW, et al. CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone. Clin Pharmacol Ther 1993; 54: 463–72PubMedCrossRefGoogle Scholar
  366. 366.
    Lelas S, Wegert S, Otton SV, et al. Inhibitors of cytochrome P450 differentially modify discriminative-stimulus and antinociceptive effects of hydrocodone and hydromorphone in rhesus monkeys. Drug Alcohol Depend 1999; 54: 239–49PubMedCrossRefGoogle Scholar
  367. 367.
    Kaplan HL, Busto UE, Baylon GJ, et al. Inhibition of cytochrome P450 2D6 metabolism of hydrocodone to hydromorphone does not importantly affect abuse liability. J Pharmacol Exp Ther 1997; 281: 103–8PubMedGoogle Scholar
  368. 368.
    Poyhia R, Vainio A, Kalso E. A review of oxycodone’s clinical pharmacokinetics and pharmacodynamics. J Pain Symptom Manage 1993; 8: 63–7PubMedCrossRefGoogle Scholar
  369. 369.
    Leow KP, Smith MT, Williams B, et al. Single-dose and steady-state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer. Clin Pharmacol Ther 1992; 52: 487–95PubMedCrossRefGoogle Scholar
  370. 370.
    Lalovic B, Phillips B, Risler LL, et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 2004; 32: 447–54PubMedCrossRefGoogle Scholar
  371. 371.
    Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993; 53: 401–9PubMedCrossRefGoogle Scholar
  372. 372.
    Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603–11PubMedCrossRefGoogle Scholar
  373. 373.
    Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods 1999; 42: 61–6PubMedCrossRefGoogle Scholar
  374. 374.
    Kristensen K, Christensen CB, Christrup LL. The μ1, μ2, δ, Κ opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995; 56: PL45–50PubMedCrossRefGoogle Scholar
  375. 375.
    de Vos JW, Geerlings PJ, van den Brink W, et al. Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts. Eur J Clin Pharmacol 1995; 48: 361–6PubMedCrossRefGoogle Scholar
  376. 376.
    Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003; 31: 742–7PubMedCrossRefGoogle Scholar
  377. 377.
    Coller JK, Joergensen C, Foster DJ, et al. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone. Int J Clin Pharmacol Ther 2007; 45: 410–7PubMedGoogle Scholar
  378. 378.
    Crettol S, Deglon JJ, Besson J, et al. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668–81PubMedCrossRefGoogle Scholar
  379. 379.
    Shiran MR, Chowdry J, Rostami-Hodjegan A, et al. A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 2003; 56: 220–4PubMedCrossRefGoogle Scholar
  380. 380.
    Wu D, Otton SV, Sproule BA, et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J Clin Pharmacol 1993; 35: 30–4PubMedCrossRefGoogle Scholar
  381. 381.
    Begre S, von Bardeleben U, Ladewig D, et al. Paroxetine increases steadystate concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22: 211–5PubMedCrossRefGoogle Scholar
  382. 382.
    Eap CB, Bertschy G, Powell K, et al. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17: 113–7PubMedCrossRefGoogle Scholar
  383. 383.
    Cobb MN, Desai J, Brown Jr LS, et al. The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 1998; 63: 655–62PubMedCrossRefGoogle Scholar
  384. 384.
    Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004; 43: 879–923PubMedCrossRefGoogle Scholar
  385. 385.
    Paar WD, Poche S, Gerloff J, et al. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol. Eur J Clin Pharmacol 1997; 53: 235–9PubMedCrossRefGoogle Scholar
  386. 386.
    Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos 2001; 29: 1146–55PubMedGoogle Scholar
  387. 387.
    Abdel-Rahman SM, Leeder JS, Wilson JT, et al. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 2002; 42: 24–9PubMedCrossRefGoogle Scholar
  388. 388.
    Poulsen L, Arendt-Nielsen L, Brosen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636–44PubMedCrossRefGoogle Scholar
  389. 389.
    Enggaard TP, Poulsen L, Arendt-Nielsen L, et al. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102: 146–50PubMedCrossRefGoogle Scholar
  390. 390.
    Slanar O, Nobilis M, Kvetina J, et al. Miotic action of tramadol is determined by CYP2D6 genotype. Physiol Res 2007; 56: 129–36PubMedGoogle Scholar
  391. 391.
    Fliegert F, Kurth B, Gohler K. The effects of tramadol on static and dynamic pupillometry in healthy subjects: the relationship between pharmacodynamics, pharmacokinetics and CYP2D6 metaboliser status. Eur J Clin Pharmacol 2005; 61: 257–66PubMedCrossRefGoogle Scholar
  392. 392.
    Wang G, Zhang H, He F, et al. Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. Eur J Clin Pharmacol 2006; 62: 927–31PubMedCrossRefGoogle Scholar
  393. 393.
    Gan SH, Ismail R, Wan Adnan WA, et al. Population pharmacokinetic modelling of tramadol with application of the NPEM algorithms. J Clin Pharm Ther 2004; 29: 455–63PubMedCrossRefGoogle Scholar
  394. 394.
    Halling J, Weihe P, Brosen K. CYP2D6 polymorphism in relation to tramadol metabolism: a study of Faroese patients. Ther Drug Monit 2008; 30: 271–5PubMedCrossRefGoogle Scholar
  395. 395.
    Gan SH, Ismail R, Wan Adnan WA, et al. Impact of CYP2D6 genetic polymorphism on tramadol pharmacokinetics and pharmacodynamics. Mol Diagn Ther 2007; 11: 171–81PubMedCrossRefGoogle Scholar
  396. 396.
    Pedersen RS, Damkier P, Brosen K. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study. Clin Pharmacol Ther 2005; 77: 458–67PubMedCrossRefGoogle Scholar
  397. 397.
    Pedersen RS, Damkier P, Brosen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur J Clin Pharmacol 2006; 62: 513–21PubMedCrossRefGoogle Scholar
  398. 398.
    Garcia-Quetglas E, Azanza JR, Sadaba B, et al. Pharmacokinetics of tramadol enantiomers and their respective phase I metabolites in relation to CYP2D6 phenotype. Pharmacol Res 2007; 55: 122–30PubMedCrossRefGoogle Scholar
  399. 399.
    Stamer UM, Lehnen K, Hothker F, et al. Impact of CYP2D6 genotype on postoperative tramadol analgesia. Pain 2003; 105: 231–8PubMedCrossRefGoogle Scholar
  400. 400.
    Dalen P, Frengell C, Dahl ML, et al. Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther Drug Monit 1997; 19: 543–4PubMedCrossRefGoogle Scholar
  401. 401.
    De Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. J Clin Psychopharmacol 2003; 23: 420–1PubMedCrossRefGoogle Scholar
  402. 402.
    Kirchheiner J, Keulen JT, Bauer S, et al. Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol. J Clin Psychopharmacol 2008; 28: 78–83PubMedCrossRefGoogle Scholar
  403. 403.
    Marchetti P, Giannarelli R, di Carlo A, et al. Pharmacokinetic optimisation of oral hypoglycaemic therapy. Clin Pharmacokinet 1991; 21: 308–17PubMedCrossRefGoogle Scholar
  404. 404.
    Marchetti P, Navalesi R. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update. Clin Pharmacokinet 1989; 16: 100–28PubMedCrossRefGoogle Scholar
  405. 405.
    Oates NS, Shah RR, Idle JR, et al. Genetic polymorphism of phenformin 4-hydroxylation. Clin Pharmacol Ther 1982; 32: 81–9PubMedCrossRefGoogle Scholar
  406. 406.
    Shah RR, Evans DA, Oates NS, et al. The genetic control of phenformin 4-hydroxylation. J Med Genet 1985; 22: 361–6PubMedCrossRefGoogle Scholar
  407. 407.
    Shah RR, Oates NS, Idle JR, et al. Genetic impairment of phenformin metabolism. Lancet 1980; 1: 1147PubMedCrossRefGoogle Scholar
  408. 408.
    Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223–41PubMedCrossRefGoogle Scholar
  409. 409.
    Oates NS, Shah RR, Idle JR, et al. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clin Pharmacol Ther 1983; 34: 827–34PubMedCrossRefGoogle Scholar
  410. 410.
    Oates NS, Shah RR, Idle JR, et al. Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation. Lancet 1981; 1: 837–8PubMedCrossRefGoogle Scholar
  411. 411.
    Wiholm BE, Alvan G, Bertilsson L, et al. Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin. Lancet 1981; 1: 1098–9PubMedCrossRefGoogle Scholar
  412. 412.
    Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Adv Exp Med Biol 2008; 630: 206–19PubMedCrossRefGoogle Scholar
  413. 413.
    Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618–29PubMedCrossRefGoogle Scholar
  414. 414.
    Jordan VC, O’Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. J Clin Oncol 2007; 25: 5815–24PubMedCrossRefGoogle Scholar
  415. 415.
    Jordan VC. Chemoprevention of breast cancer with selective oestrogenreceptor modulators. Nat Rev Cancer 2007; 7: 46–53PubMedCrossRefGoogle Scholar
  416. 416.
    Desta Z, Ward BA, Soukhova NV, et al. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062–75PubMedCrossRefGoogle Scholar
  417. 417.
    Beverage JN, Sissung TM, Sion AM, et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. J Pharm Sci 2007; 96: 2224–31PubMedCrossRefGoogle Scholar
  418. 418.
    Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003; 95: 1758–64PubMedCrossRefGoogle Scholar
  419. 419.
    Crewe HK, Notley LM, Wunsch RM, et al. Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 869–74PubMedCrossRefGoogle Scholar
  420. 420.
    Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 3402–6PubMedGoogle Scholar
  421. 421.
    Dehal SS, Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Drug Metab Dispos 1999; 27: 681–8PubMedGoogle Scholar
  422. 422.
    Ghobadi C, Gregory A, Crewe HK, et al. CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet 2008; 23: 101–5PubMedCrossRefGoogle Scholar
  423. 423.
    Poon GK, Chui YC, McCague R, et al. Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 1993; 21: 1119–24PubMedGoogle Scholar
  424. 424.
    Jacolot F, Simon I, Dreano Y, et al. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem Pharmacol 1991; 41: 1911–9PubMedCrossRefGoogle Scholar
  425. 425.
    Katzenellenbogen BS, Norman MJ, Eckert RL, et al. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 1984; 44: 112–9PubMedGoogle Scholar
  426. 426.
    Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–9PubMedCrossRefGoogle Scholar
  427. 427.
    Gjerde J, Hauglid M, Breilid H, et al. Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Ann Oncol 2008; 19: 56–61PubMedCrossRefGoogle Scholar
  428. 428.
    Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007; 25: 5187–93PubMedCrossRefGoogle Scholar
  429. 429.
    Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007; 101: 113–21PubMedCrossRefGoogle Scholar
  430. 430.
    Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006; 24: 3708–9; author reply 3709PubMedCrossRefGoogle Scholar
  431. 431.
    Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61–74PubMedCrossRefGoogle Scholar
  432. 432.
    Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312–8PubMedCrossRefGoogle Scholar
  433. 433.
    Xu Y, Sun Y, Yao L, et al. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol 2008; 19: 1423–9PubMedCrossRefGoogle Scholar
  434. 434.
    Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008; 99: 995–9PubMedCrossRefGoogle Scholar
  435. 435.
    Lim HS, Ju Lee H, Seok Lee K, et al. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007; 25: 3837–45PubMedCrossRefGoogle Scholar
  436. 436.
    Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005; 91: 249–58PubMedCrossRefGoogle Scholar
  437. 437.
    Wegman P, Vainikka L, Stal O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005; 7: R284–90PubMedCrossRefGoogle Scholar
  438. 438.
    Wegman P, Elingarami S, Carstensen J, et al. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007; 9: R7PubMedCrossRefGoogle Scholar
  439. 439.
    Kirchheiner J. CYP2D6 phenotype prediction from genotype: which system is the best? Clin Pharmacol Ther 2008; 83: 225–7PubMedCrossRefGoogle Scholar
  440. 440.
    Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008; 83: 160–6PubMedCrossRefGoogle Scholar
  441. 441.
    Takimoto CH. Can tamoxifen therapy be optimized for patients with breast cancer on the basis of CYP2D6 activity assessments? Nat Clin Pract Oncol 2007; 4: 152–3PubMedCrossRefGoogle Scholar
  442. 442.
    Wennerholm A, Dandara C, Sayi J, et al. The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clin Pharmacol Ther 2002; 71: 77–88PubMedCrossRefGoogle Scholar
  443. 443.
    Griese EU, Zanger UM, Brudermanns U, et al. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15–26PubMedCrossRefGoogle Scholar
  444. 444.
    Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and functional gene dose for the prediction of steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 2004; 50: 1623–33PubMedCrossRefGoogle Scholar
  445. 445.
    Hinrichs JW, Loovers HM, Scholten B, et al. Semi-quantitative CYP2D6 gene doses in relation to metabolic ratios of psychotropics. Eur J Clin Pharmacol 2008; 64: 979–86PubMedCrossRefGoogle Scholar
  446. 446.
    Gaedigk A, Simon SD, Pearce RE, et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234–42PubMedCrossRefGoogle Scholar
  447. 447.
    Gaedigk A, Bradford LD, Alander SW, et al. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006; 34: 563–9PubMedCrossRefGoogle Scholar
  448. 448.
    Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in Black Americans. Clin Pharmacol Ther 2002; 72: 76–89PubMedCrossRefGoogle Scholar
  449. 449.
    Gaedigk A, Ndjountche L, Gaedigk R, et al. Discovery of a novel nonfunctional cytochrome P450 2D6 allele, CYP2D6*42, in African American subjects. Clin Pharmacol Ther 2003; 73: 575–6PubMedCrossRefGoogle Scholar
  450. 450.
    Yamazaki H, Kiyotani K, Tsubuko S, et al. Two novel haplotypes of CYP2D6 gene in a Japanese population. Drug Metab Pharmacokinet 2003; 18: 269–71PubMedCrossRefGoogle Scholar
  451. 451.
    Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89–295PubMedCrossRefGoogle Scholar
  452. 452.
    Rowland P, Blaney FE, Smyth MG, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem 2006; 281: 7614–22PubMedCrossRefGoogle Scholar
  453. 453.
    Zhou SF, Liu JP, Lai XS. Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. Curr Med Chem 2009; 16: 2661–805PubMedCrossRefGoogle Scholar
  454. 454.
    Paine MJ, McLaughlin LA, Flanagan JU, et al. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6. J Biol Chem 2003; 278: 4021–7PubMedCrossRefGoogle Scholar
  455. 455.
    Mackman R, Tschirret-Guth RA, Smith G, et al. Active-site topologies of human CYP2D6 and its aspartate-301 → glutamate, asparagine, and glycine mutants. Arch Biochem Biophys 1996; 331: 134–40PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Discipline of Chinese Medicine, School of Health SciencesRMIT UniversityBundooraAustralia

Personalised recommendations